A panel of experts discusses recent advances and key clinical trial data presented at ASH 2022 concerning the treatment of multiple myeloma.
EP. 1: State of The Art in Multiple Myeloma: Year in Review 2022
A video preview for an upcoming program reviewing clinical trial data and updates in the multiple myeloma treatment landscape over the last year.
EP. 2: Induction Regimen Options in Transplant-Eligible NDMM
Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.
EP. 3: DETERMINATION, GRIFFIN, and MASTER Studies
Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.
EP. 4: Role of Transplant and Induction Therapies in NDMM
Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).
EP. 5: Induction Therapy in Transplant-Ineligible NDMM
A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.
EP. 6: Clinical Trials in Transplant-Ineligible NDMM
Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.
EP. 7: Review of Patient Subgroups in Transplant-Ineligible NDMM
Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.
EP. 8: Final Thoughts on Transplant-Ineligible Patients with MM
Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.
EP. 9: Treatment Approaches for Patients with Relapsed-Refractory MM
Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).
EP. 10: Treatment Selection of Bispecifics in Relapsed-Refractory MM
Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.
EP. 11: Rationale for Bispecific-Based Combinations in MM
Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.
EP. 12: The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options
Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.
EP. 13: Management of Bispecific Toxicities and Final Thoughts on Treatments in MM
Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.
EP. 14: Evaluating Treatment Options by Patient Type in Multiple Myeloma
Experts in the multiple myeloma space review available therapies such as CAR T-cell therapy, bispecifics, and B-cell maturation antigen–targeted agents for patients with multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512